Literature DB >> 19705574

Positive modulation of alpha7 nAChR responses in rat hippocampal interneurons to full agonists and the alpha7-selective partial agonists, 4OH-GTS-21 and S 24795.

Gretchen Y López-Hernández1, Jeffrey S Thinschmidt, Philippe Morain, Caryn Trocme-Thibierge, William R Kem, Ferenc Soti, Roger L Papke.   

Abstract

One approach for the identification of therapeutic agents for Alzheimer's disease has focused on the research of alpha7 nAChR-selective agonists such as the partial agonists 3-(4-hydroxy,2-methoxybenzylidene)anabaseine (4OH-GTS-21) and, more recently, 2-[2-(4-bromophenyl)-2-oxoethyl]-1-methyl pyridinium (S 24795). An alternative approach for targeting alpha7 nAChR has been the development of positive modulators for this receptor. In this study we examined the interactions between full or partial agonists and positive modulators of alpha7 nAChRs in situ in brain tissue. Three positive modulators were used, 5-hydroxyindole (5-HI), 1-(5-chloro-2,4-dimethoxy-phenyl)-3-(5-methyl-isoxanol-3-yl)-urea (PNU-120596), and genistein. Whole-cell recordings were performed in stratum radiatum interneurons from rat brain slices. Hippocampal interneurons were stimulated by ACh, choline, S 24795, or 4OH-GTS-21, before and after bath perfusion with the positive modulators. 5-HI was not effective at potentiating 200 microM 4OH-GTS-21-evoked responses, however 5-HI induced a sustained potentiation of responses evoked by 30 microM 4OH-GTS-21. When 1 mM ACh and 200 microM 4OH-GTS-21 were applied alternately alpha7-mediated responses to both agonists were reduced, suggesting that high concentration of 4OH-GTS-21 produces residual inhibition or desensitization and that 5-HI is not effective at overcoming receptor desensitization. Similar results were obtained with alpha7 receptors expressed in Xenopus oocytes. Interestingly, responses evoked by S 24795 were potentiated by 5-HI but not by genistein. Additionally, PNU-120596 was able to potentiate alpha7-mediated responses, regardless of the nature of the agonist. We demonstrated that the potentiation of alpha7 nAChR response would depend on the nature and the effective concentration of the agonist involved and its particular interaction with the positive modulator.

Entities:  

Mesh:

Substances:

Year:  2009        PMID: 19705574      PMCID: PMC2775526          DOI: 10.1016/j.neuropharm.2009.01.011

Source DB:  PubMed          Journal:  Neuropharmacology        ISSN: 0028-3908            Impact factor:   5.250


  50 in total

1.  Regulation of neuronal function by choline and 4OH-GTS-21 through alpha 7 nicotinic receptors.

Authors:  Vladimir V Uteshev; Edwin M Meyer; Roger L Papke
Journal:  J Neurophysiol       Date:  2002-12-04       Impact factor: 2.714

2.  5-hydroxyindole causes convulsions and increases transmitter release in the CA1 region of the rat hippocampus.

Authors:  Guido Mannaioni; Raffaella Carpenedo; Flavio Moroni
Journal:  Br J Pharmacol       Date:  2003-01       Impact factor: 8.739

3.  Activation and inhibition of native neuronal alpha-bungarotoxin-sensitive nicotinic ACh receptors.

Authors:  Vladimir V Uteshev; Edwin M Meyer; Roger L Papke
Journal:  Brain Res       Date:  2002-09-06       Impact factor: 3.252

4.  Effects at a distance in alpha 7 nAChR selective agonists: benzylidene substitutions that regulate potency and efficacy.

Authors:  Roger L Papke; Edwin M Meyer; Sophie Lavieri; Sirisha R Bollampally; Thaddeus A S Papke; Nicole A Horenstein; Yoshitsugu Itoh; Julia K Porter Papke
Journal:  Neuropharmacology       Date:  2004-06       Impact factor: 5.250

5.  Hydroxy metabolites of the Alzheimer's drug candidate 3-[(2,4-dimethoxy)benzylidene]-anabaseine dihydrochloride (GTS-21): their molecular properties, interactions with brain nicotinic receptors, and brain penetration.

Authors:  William R Kem; Vladimir M Mahnir; Laszlo Prokai; Roger L Papke; Xuefang Cao; Susan LeFrancois; Kristin Wildeboer; Katalin Prokai-Tatrai; Julia Porter-Papke; Ferenc Soti
Journal:  Mol Pharmacol       Date:  2004-01       Impact factor: 4.436

6.  Loss of nicotinic acetylcholine receptor subunits alpha4 and alpha7 in the cerebral cortex of Parkinson patients.

Authors:  Lothar Burghaus; Ulrich Schütz; Udo Krempel; Jon Lindstrom; Hannsjörg Schröder
Journal:  Parkinsonism Relat Disord       Date:  2003-06       Impact factor: 4.891

7.  Conservation within the RIC-3 gene family. Effectors of mammalian nicotinic acetylcholine receptor expression.

Authors:  Sarah Halevi; Lina Yassin; Margalit Eshel; Francisco Sala; Salvador Sala; Manuel Criado; Millet Treinin
Journal:  J Biol Chem       Date:  2003-06-23       Impact factor: 5.157

8.  Comparative pharmacology of rat and human alpha7 nAChR conducted with net charge analysis.

Authors:  Roger L Papke; Julia K Porter Papke
Journal:  Br J Pharmacol       Date:  2002-09       Impact factor: 8.739

9.  Molecular cloning, functional properties, and distribution of rat brain alpha 7: a nicotinic cation channel highly permeable to calcium.

Authors:  P Séguéla; J Wadiche; K Dineley-Miller; J A Dani; J W Patrick
Journal:  J Neurosci       Date:  1993-02       Impact factor: 6.167

10.  Modulation of spontaneous hippocampal synaptic events with 5-hydroxyindole, 4OH-GTS-21, and rAAV-mediated alpha7 nicotinic receptor gene transfer.

Authors:  Jeffrey S Thinschmidt; Gretchen Y López-Hernández; Ke Ren; Michael A King; Edwin M Meyer; Roger L Papke
Journal:  Brain Res       Date:  2008-02-14       Impact factor: 3.252

View more
  10 in total

1.  Single-channel and structural foundations of neuronal α7 acetylcholine receptor potentiation.

Authors:  Corrie J B daCosta; Chris R Free; Jeremías Corradi; Cecilia Bouzat; Steven M Sine
Journal:  J Neurosci       Date:  2011-09-28       Impact factor: 6.167

2.  Pro-cognitive activity in rats of 3-furan-2-yl-N-p-tolyl-acrylamide, a positive allosteric modulator of the α7 nicotinic acetylcholine receptor.

Authors:  A Potasiewicz; T Kos; F Ravazzini; G Puia; H R Arias; P Popik; A Nikiforuk
Journal:  Br J Pharmacol       Date:  2015-10-10       Impact factor: 8.739

Review 3.  Positive allosteric modulators as an approach to nicotinic acetylcholine receptor-targeted therapeutics: advantages and limitations.

Authors:  Dustin K Williams; Jingyi Wang; Roger L Papke
Journal:  Biochem Pharmacol       Date:  2011-05-14       Impact factor: 5.858

4.  Pharmacokinetic Limitations on Effects of an Alpha7-Nicotinic Receptor Agonist in Schizophrenia: Randomized Trial with an Extended-Release Formulation.

Authors:  William R Kem; Ann Olincy; Lynn Johnson; Josette Harris; Brandie D Wagner; Robert W Buchanan; Uwe Christians; Robert Freedman
Journal:  Neuropsychopharmacology       Date:  2017-08-21       Impact factor: 7.853

5.  Differential modulation of brain nicotinic acetylcholine receptor function by cytisine, varenicline, and two novel bispidine compounds: emergent properties of a hybrid molecule.

Authors:  Can Peng; Clare Stokes; Yann S Mineur; Marina R Picciotto; Chengju Tian; Christoph Eibl; Isabelle Tomassoli; Daniela Guendisch; Roger L Papke
Journal:  J Pharmacol Exp Ther       Date:  2013-08-19       Impact factor: 4.030

Review 6.  α7 nicotinic ACh receptors as a ligand-gated source of Ca(2+) ions: the search for a Ca(2+) optimum.

Authors:  Victor V Uteshev
Journal:  Adv Exp Med Biol       Date:  2012       Impact factor: 2.622

7.  Activation of functional α7-containing nAChRs in hippocampal CA1 pyramidal neurons by physiological levels of choline in the presence of PNU-120596.

Authors:  Bopanna I Kalappa; Alexander G Gusev; Victor V Uteshev
Journal:  PLoS One       Date:  2010-11-12       Impact factor: 3.240

8.  Physiological concentrations of choline activate native alpha7-containing nicotinic acetylcholine receptors in the presence of PNU-120596 [1-(5-chloro-2,4-dimethoxyphenyl)-3-(5-methylisoxazol-3-yl)-urea].

Authors:  Alexander G Gusev; Victor V Uteshev
Journal:  J Pharmacol Exp Ther       Date:  2009-11-18       Impact factor: 4.030

9.  Activation and desensitization of nicotinic alpha7-type acetylcholine receptors by benzylidene anabaseines and nicotine.

Authors:  Roger L Papke; William R Kem; Ferenc Soti; Gretchen Y López-Hernández; Nicole A Horenstein
Journal:  J Pharmacol Exp Ther       Date:  2009-02-17       Impact factor: 4.030

10.  The nAChR Chaperone TMEM35a (NACHO) Contributes to the Development of Hyperalgesia in Mice.

Authors:  Sergey G Khasabov; Victoria M Rogness; Montana B Beeson; Lucy Vulchanova; Li-Lian Yuan; Donald A Simone; Phu V Tran
Journal:  Neuroscience       Date:  2021-01-07       Impact factor: 3.590

  10 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.